

業 績 目 録（令和6年）

大学院科目名：医療フロンティア展開学

（A-a）英文著書

（A-b）和文著書

1. 加藤則人. 紅皮症（をみれば）. 皮膚疾患 最新の治療 2025-2026. P.56, 2024. 南江堂.

（B-a）英文総説

1. Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield L, Eyerich K, Gooderham M, Guttman-Yassky E, Hijnen DJ, Irvine A, Katoh N, Murrell DF, Leshem YA, Levin A, Vittrup I, Olydam JI, Orfali RL, Paller A, Renert-Yuval Y, Rosmarin D, Silverberg J, Thyssen J, Ständer S, Stefanovic N, Todd G, Yu J, Simpson E. A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. *Br J Dermatol* 192; 135-143, 2024. doi: 10.1093/bjd/ljae342.
2. Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, Tanaka A, Tanizaki H, Tsunemi Y, Nakahara T, Nagao M, Narita M, Hide M, Fujisawa T, Futamura M, Masuda K, Matsubara T, Murota H, Yamamoto-Hanada K, Furuta J. English version of clinical practice guidelines for the management of atopic dermatitis 2024. *J Dermatol* 2024 doi: 10.1111/1346-8138.17544.

（B-b）和文総説

1. 佐伯秀久、大矢幸弘、荒川浩一、市山進、勝沼俊雄、加藤則人、田中暁生、谷崎英昭、常深祐一郎、中原剛士、長尾みづほ、成田雅美、秀道広、藤澤隆夫、二村昌樹、益田浩司、松原知代、室田浩之、山本貴和子、古田淳一. アトピー性皮膚炎診療ガイドライン 2024 日皮会誌 134; 2741-2843, 2024. アレルギー 73; 1025-1125, 2024.

（C-a）英文原著

1. Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J, Niiyama H, Sasaki T, Raymundo EM, Saeki H. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: analysis of the 3-year phase 3 rising up study. *Dermatol Ther (Heidelb)* 14; 213-232, 2024. doi: 10.1007/s13555-023-01071-2.

2. Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Hanada T, Igawa K. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J). *Br J Dermatol* 2024. doi: 10.1093/bjd/ljae394.
3. Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Igawa K. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate to severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). *Curr Med Res Opin* 2024, doi: 10.1080/03007995.2024.2436982.
4. Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Montmayeur S, Katoh N. Lebrikizumab combined with topical corticosteroids improves patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis. *Acta Derm Venereol* 2024; 104: adv34375. doi: 10.2340/actadv.v104.34375.
5. Kaneko S, Nakahara T, Murota H, Tanaka A, Kataoka Y, Kakamu T, Kanoh H, Watanabe Y, Katoh N. Physician's perspective and practices in atopic dermatitis management: A cross-sectional online survey in Japan. *J Cutan Immunol Allergy* 2024. doi: 10.3389/jcia.2024.12567.
6. Asai J, Maruyama A, Katoh N. Lupus miliaris disseminatus faciei successfully treated with topical adapalene and benzoyl peroxide. *J Dermatol*. 51: e214-e215, 2024. doi: 10.1111/1346-8138.17119. (皮膚科学と共同)
7. Asai J, Ohta R, Maruyama A, Katoh N. Lichen planus pigmentosus successfully treated with topical delgocitinib. *J Dermatol* 51; e243-e244, 2024. doi: 10.1111/1346-8138.17151. (皮膚科学と共同)
8. Tamagawa-Mineoka R, Taniguchi M, Ioka N, Hattori J, Mizutani H, Masuda K, Katoh N. Depigmented contact dermatitis due to phenylbenzimidazole sulfonic acid contained in skin lotion. *Contact Dermatitis* 91; 259-260, 2024. doi: 10.1111/cod.14588. (皮膚科学と共同)
9. Mizutani H, Tamagawa-Mineoka R, Ishikawa T, Hattori J, Ioka N, Masuda K, Katoh N. Allergic contact dermatitis to 1,6-hexanediol diacrylate in a factory worker. *J Cutan Immunol Allergy* 2024. doi: 10.3389/jcia.2024.12645. (皮膚科学と共同)
10. Kawasaki-Nagano M, Tamagawa-Mineoka R, Kurioka T, Arakawa Y, Nakanishi M, Kishida M, Nishigaki H, Hashidate-Yoshida T, Shindou H, Katoh N. Lysophosphatidylcholine acyltransferase 2 contributes to increased allergic and

- irritant inflammation in mice. *Exp Dermatol* 33; e70015, 2024. doi: 10.1111/exd.70015. (皮膚科学と共同)
11. Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A. Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1. *Am J Clin Dermatol* 25; 139-148, 2024. doi: 10.1007/s40257-023-00817-0.
 12. Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuchi Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis. *Allergol Int* 73; 332-334, 2024. doi: 10.1016/j.alit.2023.12.001.
 13. Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide H, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuchi Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Tanese K, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. *J Allergy Clin Immunol Glob* 3: 100317, 2024, doi: 10.1016/j.jacig.2024.100317.
 14. Kim S Thomas KS, Howells L, Leshem YA, Simpson EL, Apfelbacher C, Spuls PI, Schmitt J, Gerbens LAA, Jacobson ME, Katoh N, Williams HC, Stuart BL, on behalf of the Harmonising Outcome Measures for Eczema (HOME) initiative. How to use the HOME Core Outcome Set for atopic dermatitis trials -a users' guide. *Br J Dermatol* 190; 527-535, 2024. doi: 10.1093/bjd/ljad497.
 15. Saeki H, Kataoka Y, Etoh T, Katoh N, Teramukai S, Tajima Y, Fujita H, Ardeleanu M, Arima K. Correlation analysis of clinician- and patient-reported outcomes among Japanese adults with atopic dermatitis. *Dermatol Ther (Heidelb)* 14; 533-543, 2024. doi: 10.1007/s13555-023-01094-9.
 16. Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS,

- Williams H, Katoh N, Howells L, Schmitt J, Deckert S, Seshadri R, Simpson EL. Measuring signs of atopic dermatitis in clinical practice: A HOME-CP consensus statement. *JAMA Dermatol* 160; 878-886, 2024. doi: 10.1001/jamadermatol.2024.1162.
17. Wollenberg A, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Silverberg JI. Patient-reported burden in adults with atopic dermatitis: an international qualitative study. *Arch Dermatol Res* 316; 380, 2024. doi: 10.1007/s00403-024-03130-w.
 18. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Barbarot S, Rademaker M, Fomina D, Guterthum J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof M, Lio P, Wollenberg A. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. *J Eur Acad Dermatol Venereol* 38; 2139-2148, 2024, doi: 10.1111/jdv.20229.
 19. Jacobson ME, Morimoto RY, Leshem YA, Howells L, Williams HC, Grinich E, Gerbens LAA, Spuls PI, Schmitt J, Staley B, Baghoomian W, Katoh N, Thomas KS, Apfelbacher C, Simpson EL. The eczema area and severity index - an update of progress & challenges in its measurement of atopic dermatitis after 20 years of use. *J Eur Acad Dermatol Venereol* 2024, doi: 10.1111/jdv.20248.
 20. Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide M, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuchi Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Tanese K, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. *J Allergy Clin Immunol Glob* 2024; 3(4): 100317. doi: 10.1016/j.jacig.2024.100317.
 21. Shoji J, Asada Y, Adachi R, Inada N, Uchio E, Kataoka Y, Katoh N, Kishimoto T, Shimizu E, Sumi T, Takamura E, Nanba K, Hara Y, Harada K, Hirota A, Fukushima A, Fukuda K, Fujishima H, Matsuzawa M, Matsuda A, Mimura T, Miyazaki D, Hiroyuki Y, Yamamoto K, Kizu K, Ebihara N. Questionnaire survey of ophthalmic allergists for dupilumab-associated ocular surface disease in Japan. *Allergol Int* 2024, doi: 10.1016/j.alit.2024.10.004.

Ueno M, Imai K, Tomioka Y, Horiguchi G, Kameda T, Teramukai S, Tsujikawa A, Inatomi T, Sotozono C, Kinoshita S.

Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy. Jpn J Ophthalmol. 2024 Nov;68(6):660-668.

2

Aziza Y, Imai K, Itoi M, Yoshioka H, Komai S, Kitazawa K, Sitompul R, Ueta M, Fukuoka H, Inatomi T, Kinoshita S, Sotozono C.

Strategic combination of cultivated oral mucosal epithelial transplantation and postoperative limbal-rigid contact lens-wear for end-stage ocular surface disease: a retrospective cohort study.

Br J Ophthalmol. 2024 Jul 23;108(8):1177-1183.

(C-b) 和文原著

1. 大堀侑紀、峠岡理沙、益田浩司、加藤則人. アトピー性皮膚炎患者およびその養育者の就労・就学に与える影響の調査. 日皮会誌 134; 2287-2298: 2024.

(D) 学会発表等

1. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Barbarot S, Lee WJ, Calimlim BM, Gamelli A, Wollenberg A. Treatment with upadacitinib increases the achievement of minimal disease activity among patients with moderate-to-severe atopic dermatitis: results from phase 3 studies (Measure up 1 and Measure Up 2). 2024 Annual Meeting of American Academy of Dermatology, San Diego, CA, USA, March 8-12, 2024.
2. Gold LS, Thaçi D, Katoh N, Shi V, Irvine A, Piruzeli MLB, Zhao F, Montmayeur S, Gallo G, Jimenez G, de Bruin-Weller M. Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials. 2024 Annual Meeting of American Academy of Dermatology, San Diego, CA, USA, March 8-12, 2024.
3. Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Montmayeur S, Katoh N. Lebrikizumab combined with topical corticosteroids improves patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis. 2024 Annual Meeting of American Academy of Dermatology, San Diego, CA, USA, March 8-12, 2024.

4. Pereira MP, Stevanovic K, Meesch C, van Hofman I, Vaswani PS, Beck L, de Bruin-Weller M, Cork M, Katoh N, Wollenberg A, Worm M, Werfel T, Kocatürk E, Zuberbier T; on behalf of GA 2LEN ADCARE. Systemic treatment of atopic dermatitis in pregnancy: the physician's perspective. European Academy of Allergy and Clinical Immunology Hybrid Congress 2024, Valencia, Spain, 31 May, 2024.
5. Tanaka A, Igawa K, Takahashi H, Torisu-Itakura H, Morisaki Y, Montmayeur S, Pierce E, Katoh N. Lebrikizumab demonstrated early improvement in both clinician and patient reported outcomes as measured by SCORAD in Japanese patients with moderate-to-severe atopic dermatitis. EADV2024. Amsterdam, Netherland, 25 September, 2024.
6. Reich A, Weidinger S, Shi V, Katoh N, Gray C, Bernigaud C, Rahawi K. Impact of amltelimab (an anti-OX40 Ligand antibody) on atopic dermatitis of the head and neck: post hoc results from the STREAM-AD phase 2b study of moderate-to-severe atopic dermatitis. EADV2024. Amsterdam, Netherland, 25 September, 2024.
7. Chovatiya R, Ständer S, Mendes-Bastos P, Katoh N, Swanson E, Calimlim BM, Li C, Truong CB, Grada A, Sanchez CS, Goel S, Blauvelt A. Sustained improvement in patient-reported skin symptoms of atopic dermatitis with long-term upadacitinib use: 140-week atopic dermatitis symptom scale (ADerm-SS) results of phase 3 Measure Up 1 and Measure Up 2 clinical trials. EADV2024. Amsterdam, Netherland, 25 September, 2024.
8. Eyerich K, Bastos PM, Holzer G, Jain V, Katoh N, Luna PC, Segura PC, Lane M, Pechonkina A, Grada A, Moreira A, Bunick C. Efficacy of upadacitinib in treating atopic dermatitis in the head and neck regions. EADV2024. Amsterdam, Netherland, 25 September, 2024.
9. Adachi T, Miyagawa A, Hirota M, Yonekura S, Ogawa Y, Futamura M, Ako R, Nakajima S, Inomata T, Ishikawa T, Akasaki Y, Katoh N. Comprehensive collection of unmet needs in atopic dermatitis patients utilizing clustering, machine learning, and natural language processing analysis. KAAACI Seoul International Congress 2024, 10 May, 2024.
10. Wollenberg A, Simpson EL, Leshem YA, Taieb A, Katoh N, Chao J, Rossi AB, Praestgaard A. SCORAD severity band threshold analysis from dupilumab clinical trials in adults with moderate-to-severe atopic dermatitis. RAD Spring 2024, June 8, Chicago, IL, USA.
11. Irvine A, Silverberg JI, Bunick C, Vleugels RA, Chovatiya R, Lima H, Torres T, Eyerich K, Imafuku S, Katoh N, Xinghua G, Calimlim B, Hu X, Yang Y, Dilley D, Levy G, Goel S, Altman K, Pechonkina A. Efficacy and safety of upadacitinib at

188 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results. RAD 2024: Revolutionizing Atopic Dermatitis - Virtual Symposium 2024. 2024. 12. 8.

Ⅲ) 国際学会における一般発表

1. Poster

Informed Consent Forms for Corneal Diseases in the Development of Novel Regenerative Medicine

Kojiro Imai, Morio Ueno, Chie Sotozono, Shigeru Kinoshita

Asia Cornea Society. 2024 Sep 26-28 Jakarta, Indonesia

E 研究助成（競争的研究助成金）

1. 加藤則人. 厚生労働科学研究費補助金 免疫・アレルギー疾患政策研究事業（研究分担者）. 金属アレルギーの新規管理法の確立に関する研究.
2. 加藤則人. 厚生労働科学研究費補助金 免疫・アレルギー疾患政策研究事業（研究分担者）. 学校・保育所等におけるアレルギー疾患を有するこどもの安心・安全・生き生きとした活動を保証する生活管理指導表の運用・管理体制向上をめざす研究.
3. 加藤則人. 日本医療研究開発機構 医薬品等規制調和・評価研究事業（研究分担者）. 医薬部外品・化粧品の安全性評価のための複数の皮膚感作性試験代替法を組合せた評価体系に関するガイドンス作成.
4. 加藤則人. 日本医療研究開発機構 免疫アレルギー疾患実用化研究事業（研究分担者）. アトピー性皮膚炎をモデルとした次世代リバーストランスレーショナル研究基盤構築に向けた研究.
5. 加藤則人. 日本医療研究開発機構 免疫アレルギー疾患実用化研究事業（研究分担者）. 乳児期発症のアトピー性皮膚炎の予後を追跡しアレルギーマーチへの診療の影響と危険因子を探索する前向きコホート研究.
6. 加藤則人. 日本医療研究開発機構 免疫アレルギー疾患実用化研究事業（研究分担者）. 経皮感作対策による食物アレルギー発症予防研究.
7. 今井浩二郎（代表）文部科学省科学研究費補助金基盤研究（C）令和4～6年度 再生医療法が日本の再生医療開発に及ぼす影響の検討 助成金額 110 万円（総額 330 万円）